Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:16:07.193Z.
Calculation as of: 2026-10-06T16:16:07.193Z.
Quote observation: 2026-10-06T16:13:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c0c25a561797b8251bbc96a681ec43d66f95a8f813bb62f19698de697ac6593e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$50.78M
EV/EBITDA Ratio
N/A
TTM Avg
35309.82x
3Y Avg
79402.66x
5Y Avg
79402.66x
Market Cap
$49.90M
EV/EBITDA Ratio
N/A
TTM Avg
310.55x
3Y Avg
191.07x
5Y Avg
171.86x
Market Cap
$51.13M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.28M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.34M
EV/EBITDA Ratio
N/A
TTM Avg
335.70x
3Y Avg
335.70x
5Y Avg
335.70x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Celularity Inc. (CELU) | $50.58M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $50.78M | N/A | 35309.82x | 79402.66x | 79402.66x |
| Microbot Medical Inc. (MBOT)vs › | $49.90M | N/A | 310.55x | 191.07x | 171.86x |
| Apollomics, Inc. (APLM)vs › | $49.85M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.13M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.28M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.34M | N/A | 335.70x | 335.70x | 335.70x |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $51.05M | N/A | N/A | N/A | N/A |
| Lite Strategy, Inc. (LITS)vs › | $48.49M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
